Regeneron Pharmaceuticals

Make a delay and accumulation of outstanding tasks Full stop
Biotech

Regeneron does 180 on 2seventy lymphoma CAR-T

Regeneron has given up on a CAR-T candidate acquired from 2seventybio last year, before it finished a phase 1/2 lymphoma study.
James Waldron Oct 23, 2025 10:57am
accelerated

Regeneron, Sanofi receive 1- to 2-month priority review vouchers

Oct 17, 2025 8:30am
hearing audio waves

Regeneron shares updated data on hearing loss gene therapy

Oct 12, 2025 10:18am
Businessman climbing steps to pluck a star from the sky

Regeneron's ultrarare disease phase 3 hits, teeing up filings

Sep 17, 2025 9:31am
Cat

Regeneron antibodies post ph. 3 wins against cat, pollen allergy

Sep 8, 2025 9:54am
dominoes stop stall halt end red

'Several concerning observations': FDA sheds light on rejections

Sep 5, 2025 10:45am